BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25445421)

  • 21. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
    Eames T; Landthaler M; Karrer S
    Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
    [No Abstract]   [Full Text] [Related]  

  • 22. Acneiform Rash With Ramucirumab and Paclitaxel in a Patient With Recurrent Esophageal Cancer.
    Moore DC
    Am J Ther; 2018; 25(5):e557-e558. PubMed ID: 28767454
    [No Abstract]   [Full Text] [Related]  

  • 23. Cetuximab-induced acne.
    Molinari E; De Quatrebarbes J; André T; Aractingi S
    Dermatology; 2005; 211(4):330-3. PubMed ID: 16286741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Acute acneform eruption secondary to cetuximab with good response to metronidazole].
    Jiménez-Puya R; Gómez-García F; Rodríguez-Bujaldón A; Moreno-Giménez JC
    Actas Dermosifiliogr; 2007 Nov; 98(9):648-9. PubMed ID: 17961460
    [No Abstract]   [Full Text] [Related]  

  • 27. Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab.
    Monti M; Mancini LL; Ferrari B; Rahal D; Santoro A
    J Clin Oncol; 2003 Dec; 21(24):4651-3. PubMed ID: 14673056
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment with adapalene of cetuximab-induced acneiform eruptions.
    Taguchi K; Fukunaga A; Okuno T; Nishigori C
    J Dermatol; 2012 Sep; 39(9):792-4. PubMed ID: 22168666
    [No Abstract]   [Full Text] [Related]  

  • 29. Incidence of brain metastases in early stage HER2 3+ breast cancer patients; is there a role for brain CT in asymptomatic patients?
    Tomasevic ZI; Rakocevic Z; Tomasevic ZM; Milovanovic Z; Inic M; Kolarevic D; Lukic V; Kovac Z
    J BUON; 2012; 17(2):249-53. PubMed ID: 22740201
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer.
    Gholam D; Chebib A; Hauteville D; Bralet MP; Jasmin C
    Anticancer Drugs; 2007 Aug; 18(7):835-7. PubMed ID: 17581308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twelve cases of acneiform eruptions while on anti-CTLA4 therapy.
    Welborn M; Kubicki SL; Garg N; Patel AB
    Support Care Cancer; 2020 Jun; 28(6):2499-2502. PubMed ID: 32147760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of topical benzoyl peroxide for prolonged acneiform eruptions induced by cetuximab and panitumumab: A multicenter, phase II trial.
    Tsutsui K; Kikuchi K; Nozawa K; Takashima A; Tsuchiyama K; Namikawa K; Aiba S; Yamazaki N
    J Dermatol; 2021 Jul; 48(7):1077-1080. PubMed ID: 33682955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
    Huemer F; Gampenrieder SP; Schlattau A; Greil R
    Clin Breast Cancer; 2014 Feb; 14(1):e17-20. PubMed ID: 24246725
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful treatment with weekly paclitaxel and carboplatin combined with trastuzumab in a patient with heavily pretreated metastatic breast cancer.
    Kikuchi Y; Takano M; Kudoh K; Kita T; Sato K
    Eur J Obstet Gynecol Reprod Biol; 2008 Dec; 141(2):189-91. PubMed ID: 18778887
    [No Abstract]   [Full Text] [Related]  

  • 35. Differences in Management Between Dermatologists and Oncologists for Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.
    Oliel S; Bierbrier R; D'Aguanno K; Esfahani K; Pehr K
    J Cutan Med Surg; 2024; 28(1):79-81. PubMed ID: 38156654
    [No Abstract]   [Full Text] [Related]  

  • 36. Acneiform eruption as a probable paradoxical reaction to adalimumab.
    Fernández-Crehuet P; Ruiz-Villaverde R
    Int J Dermatol; 2015 Aug; 54(8):e306-8. PubMed ID: 24697221
    [No Abstract]   [Full Text] [Related]  

  • 37. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.
    Elosua-Gonzalez M; Lopez-Estebaranz JL; Garcia-Zamora E; Vela-Ganuza M; Rodrigez-Vasquez X
    Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
    Ocvirk J; Cencelj S
    J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
    Fernandez-Galar M; España A; López-Picazo JM
    Clin Exp Dermatol; 2004 Mar; 29(2):138-40. PubMed ID: 14987267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer.
    Baselga J; Smith BL; Rafferty EA; Bombonati A
    N Engl J Med; 2012 May; 366(21):2018-26. PubMed ID: 22621630
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.